Company intelligence / Profile preview

Adenocyte

Ownership: Private
Development stage: Commercial

Overview

Adenocyte has developed LINFU®, an FDA-cleared, non-invasive ultrasound device that increases epithelial cell exfoliation into body fluids. This results in improved samples for dysplasia and cancer screening. The company claims this approach can significantly enhance the diagnostic yield of cytological specimens used in early detection programs.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Partnerships

No major pharmaceutical or biotech partnerships are disclosed on public sources.

Beyond the preview

Go deeper on Adenocyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenocyte.

Explore the full profile